Sjoerd Hendrikus VAN DER BURG,Tom H. M. OTTENHOFF,Annemieke GELUK,Maria Johanna Philomena SCHOENMAEKERS-WELTERS,Annemieke M. DE JONG,Rienk OFFRINGA,Cornelis Johannes Maria MELIEF,Rene Everardus Maria
申请号：
US14832060
公开号：
US20150343053A1
申请日:
2015.08.21
申请国别(地区):
US
年份:
2015
代理人:
摘要：
Epitopes derived from human papilloma virus and peptides having a size of about 22-45 amino acid residues comprising minimal T cell epitopes are disclosed. Also disclosed are clinically relevant approaches for immunizing subjects against (Myco) bacterially and/or virally infected cells or tumor cells. Peptide sequences of 22-35 amino acid residues in length can induce both peptide-specific CD8+ cytolytic cells and CD4+ T-helper cells. Moreover, vaccination with 22-35 residue long peptides results in a more vigorous CD8+ cytolytic T-cell response than vaccination with peptides of the exact minimal CTL epitope length. The intrinsic capacity of certain minimal CTL epitopes which instead of activating cytolytic effector cells tolerize these cytolytic cells, can be overcome by use of these 22-35 amino acid long peptides. Also disclosed are clinically relevant approaches for vaccination and/or treatment of subjects against HPV and methods and uses suited to treat subjects suffering from progressive lesions and/or cervical cancer.
